{"entity":{"id":"f-stephen-hodi","kind":"person","name":"F. Stephen Hodi","aka":[],"tldr":"First author of the 2010 ipilimumab trial that proved immunotherapy could extend survival in melanoma.","summary":"F. Stephen Hodi is Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber Brigham Cancer Center. He is known as first author of the 2010 phase 3 ipilimumab trial that opened the checkpoint-inhibitor era in melanoma, and later for the long-term follow-up of nivolumab plus ipilimumab in CheckMate 067. His selected papers report ipilimumab in metastatic melanoma and the long-term results of nivolumab with or without ipilimumab in advanced melanoma. He now directs Dana-Farber's immuno-oncology centre and continues to work on CTLA-4 and PD-1 blockade.","asOf":"2026-09-08","links":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/f-stephen-hodi"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hodi%20FS%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["ctla4","pd1"],"drugs":["ipilimumab","nivolumab"],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":["checkmate-067"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Melanoma Center and Center for Immuno-Oncology","institutionId":"dana-farber","specialisms":["Melanoma","Checkpoint inhibitors","Immuno-oncology"],"profiles":[{"label":"Dana-Farber profile","url":"https://www.dana-farber.org/find-a-doctor/f-stephen-hodi"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hodi%20FS%5BAuthor%5D"}],"papers":[{"title":"Improved survival with ipilimumab in patients with metastatic melanoma","journal":"New England Journal of Medicine","year":2010,"url":"https://doi.org/10.1056/NEJMoa1003466","doi":"10.1056/NEJMoa1003466"},{"title":"Long-term survival with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma (CheckMate 067)","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2407417","doi":"10.1056/NEJMoa2407417"},{"title":"CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate%20067%2010-year%20nivolumab%20ipilimumab%20melanoma%20Wolchok%20NEJM%202025"},{"title":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","journal":"New England Journal of Medicine","year":2012,"url":"https://doi.org/10.1056/NEJMoa1200690","doi":"10.1056/NEJMoa1200690"}]},"route":"/people/f-stephen-hodi/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/"},{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","route":"/institutions/sitc/"}],"trial":[{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/"}],"paper":[{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/"},{"id":"paper-hodi-ipilimumab-melanoma-nejm-2010","kind":"paper","name":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","route":"/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/"},{"id":"paper-topalian-anti-pd1-nejm-2012","kind":"paper","name":"Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer","route":"/key-papers/paper-topalian-anti-pd1-nejm-2012/"}]}}